BioCentury
ARTICLE | Distillery Therapeutics

Neurology

November 15, 2017 7:21 PM UTC

Mouse studies suggest inhibiting the eIF4E-eIF4G1 interaction could help treat fragile X syndrome. In a mouse model of fragile X syndrome, a tool compound that inhibits the eIF4E-eIF4G1 interaction increased dendritic spine numbers in hippocampal neurons and decreased memory deficits compared with vehicle. Next steps include development of additional eIF4E-eIF4G1 inhibitors.

Onconova Therapeutics Inc. has ON 013100, a small molecule eIF4E inhibitor, in preclinical testing for cancer...